| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Cancer Research Campaign Department of Medical Oncology, Cancer Research Campaign Beatson Laboratories, Glasgow G61 1BD [N. J. M., M. I., Y. T. K., R. B.], and Beatson Oncology Unit, Western Infirmary, Glasgow G11 [J. P.], United Kingdom
Loss of expression of mismatch repair (MMR) proteins leads to resistance of tumor cells to a variety of DNA-damaging agents, including bifunctional alkylating and monofunctional methylating agents such as cis-diaminedichloroplatinum II (CDDP) and N'-methyl-N-nitrosourea (MNU). It has been suggested that coupling to cell death does not occur in the absence of MMR, but instead, DNA lesions are bypassed during replication, giving a drug-tolerant phenotype. In the present study, we have used aphidicolin (Ap), an inhibitor of DNA polymerases, to study the role of replicative bypass in drug resistance mediated by loss of MMR. We have examined the survival of matched ovarian carcinoma cell lines with known MMR status after sequential treatment with CDDP or MNU and Ap. We show that Ap increases the sensitivity of MMR-deficient cell lines to CDDP and MNU to a greater extent than their MMR-proficient counterparts. Furthermore, loss of MMR correlates with loss of CDDP-induced G2 arrest, but this is partially restored after Ap treatment. These data support Ap sensitizing drug-resistant cancer cells that have lost MMR to CDDP and MNU and suggest that the potential use of Ap as a modulator of drug resistance should be targeted to MMR-defective tumors.
This article has been cited by other articles:
|
|
 |
|
  V. O'Brien and R. Brown Signalling cell cycle arrest and cell death through the MMR System Carcinogenesis, April 1, 2006; 27(4): 682 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Kvols Radiation Sensitizers: A Selective Review of Molecules Targeting DNA and non-DNA Targets J. Nucl. Med., January 1, 2005; 46(1_suppl): 187S - 190S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gifford, J. Paul, P. A. Vasey, S. B. Kaye, and R. Brown The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients Clin. Cancer Res., July 1, 2004; 10(13): 4420 - 4426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Curtin, L.-Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan-Koch, S. E. Webber, B. W. Durkacz, H. A. Calvert, Z. Hostomsky, et al. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells Clin. Cancer Res., February 1, 2004; 10(3): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Gerson Clinical Relevance of MGMT in the Treatment of Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2388 - 2399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and Molecular Pharmacology of Oxaliplatin Mol. Cancer Ther., January 1, 2002; 1(3): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marchini, G. Damia, M. Broggini, G. Pennella, M. Ripamonti, A. Marsiglio, and C. Geroni 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms Cancer Res., March 1, 2001; 61(5): 1991 - 1995. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Berardini, A. Mazurek, and R. Fishel The Effect of O6-Methylguanine DNA Adducts on the Adenosine Nucleotide Switch Functions of hMSH2-hMSH6 and hMSH2-hMSH3 J. Biol. Chem., September 1, 2000; 275(36): 27851 - 27857. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
